Where retatrutide actually is - August 2026
Retatrutide (LY3437943) is Eli Lilly's investigational GIP/GLP-1/glucagon triple receptor agonist. In the Phase 2 trial published in the New England Journal of Medicine, participants on the highest dose lost a mean of about 24% of body weight at 48 weeks - the largest reduction reported for any anti-obesity medication in a Phase 2 setting. That result is why search interest exploded, and why a gray market appeared years before approval.
The Phase 3 TRIUMPH program is ongoing. Lilly has signaled a regulatory submission expected around early 2027, which would place a realistic FDA decision in 2027-2028 assuming standard review. No submission, no PDUFA date, no accelerated pathway has been publicly confirmed as of August 2026.
What the FDA has said
- Retatrutide is not approved for any indication.
- It cannot currently be legally compounded - unlike semaglutide and tirzepatide during their official shortage periods, there is no shortage-based pathway, because there is no approved product to be in shortage.
- The agency has warned about unapproved GLP-1 products sold online, including products marketed as “research use only” retatrutide, citing unknown purity, identity, and dosing risks.
Translation: anything sold as retatrutide today - telehealth, med-spa, or “research chemical” website - is either unlawful, unverifiable, or both.
Signals we watch for the next update
- TRIUMPH Phase 3 topline readouts (obesity endpoints first).
- Lilly's BLA/NDA submission announcement - the real starting gun.
- Any FDA advisory-committee scheduling.
- New FDA warning letters naming sellers.
What approval day will change
On approval, retatrutide becomes a branded prescription product with a list price, insurance criteria, and a legitimate telehealth prescribing route - the same arc semaglutide and tirzepatide followed. Until then, the only legal ways to take it are inside a clinical trial.
Doing dose math for a trial protocol or preparing for the approved product? The retatrutide calculator handles mg-to-units conversion - math only.
Changelog
| Month | Status change |
|---|---|
| Aug 2026 | Tracker launched. Phase 3 ongoing; no submission filed; compounding remains unlawful. |
Sources: NEJM Phase 2 publication (Jastreboff et al.), Eli Lilly investor communications, FDA drug-alert statements on unapproved GLP-1 products. This page reports regulatory facts and is not medical advice.